Skip to content

Struvite Stones Antibiotic Study

A Prospective Randomized Trial of 2 Weeks vs 3 Months of Antibiotics Post Percutaneous Nephrolithotomy for the Prevention of Infection-Related Kidney Stones

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02375295
Enrollment
28
Registered
2015-03-02
Start date
2015-03-31
Completion date
2023-12-31
Last updated
2022-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stones

Keywords

struvite, infection, stones, calculi, antibiotics

Brief summary

The aim of this research is to determine an effective antibiotic regimen following definitive surgical therapy of kidney stones caused by bacterial infection (struvite stones).

Detailed description

Struvite stones or infection stones are a subset of kidney stones that are related to bacterial infection. They only make up 15% of all kidney stones, but account for a much higher percentage of mortality (up to 67%) compared to other stones-due to the infectious component. Treatment is to ensure 100% eradication of the stone with surgery followed by antibiotics to eliminate the infection. Failure to eliminate the bacteria results in the stone growing back quickly. It is unknown how long antibiotics should be administered immediately after surgery-some urologists give 2-4 weeks while others give 2-3 months. We seek to randomize patients to receive 2 weeks of antibiotics or 3 months of antibiotics after surgery to remove all the kidney stones. We will see patients at 3, 6, and 12 months with x-rays and to test their urine for bacterial infections. This is a multi-centre study with participating 12 sites across North America.

Interventions

DRUGciprofloxacin, cotrimoxazole-trimethoprim, macrodantin

Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or Female. 2. No age restriction. 3. Diagnosed with an infection related stone. 4. Medically fit for definitive surgical management of stone. 5. Life expectancy greater than one year. 6. Stone free after definitive surgical therapy defined as fragments less than 3mm.

Exclusion criteria

1. Patients with medical comorbidities preventing them from definitive surgical therapy. 2. Patients with persistent stone burden following definitive surgical therapy.

Design outcomes

Primary

MeasureTime frameDescription
any recurrent kidney stones6 monthsRadiologic recurrence of calculi in the location of original treatment at or before 6 months following definitive surgical therapy.

Secondary

MeasureTime frameDescription
treated site stone recurrence rates1 yearRadiologic recurrence of calculi in the location of original treatment at or before 12 months following definitive surgical therapy
Clostridiuum difficile colitis1 yearAntibiotic related complications such as Clostridiuum difficile colitis infections.
ER visitPOD1In hospital sepsis and febrile episodes.
Readmission for sepsis.3 monthsReadmission for sepsis.
UTI1 yearPositive urine cultures at any point within 1 year from surgical therapy.
Morbidity or mortality related to sepsis or renal failure3 monthsMorbidity or mortality related to sepsis or renal failure
Repeat surgical procedures for stone recurrence3 monthsRepeat surgical procedures for stone recurrence
Ancillary procedures for stones such as ureteric stenting and nephrostomy tubes3 monthsAncillary procedures for stones such as ureteric stenting and nephrostomy tubes
Readmission for renal colic3 monthsReadmission for renal colic

Countries

Canada, United States

Contacts

Primary ContactOlga Arsovska
olga.arsovska@ubc.ca6048754111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026